Affinage

FZD7

Frizzled-7 · UniProt O75084

Length
574 aa
Mass
63.6 kDa
Annotated
2026-06-09
84 papers in source corpus 30 papers cited in narrative 30 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FZD7 is a seven-transmembrane Wnt receptor that functions as a context-dependent signaling hub for both canonical Wnt/β-catenin and non-canonical Wnt pathways, governing stem cell self-renewal, developmental patterning, and tumor-initiating activity (PMID:18681827, PMID:33331818). In its canonical mode, FZD7 partners with the co-receptor LRP6 to drive β-catenin stabilization and TCF-dependent transcription; engineered selective engagement of FZD7 with LRP6 is sufficient to activate β-catenin signaling and initiate mesendodermal/mesodermal differentiation in human pluripotent stem cells, with FZD7 producing distinct, more rapidly dampened β-catenin kinetics than FZD2 (PMID:33331818, PMID:39824186). This canonical axis maintains pluripotency in human embryonic stem cells and drives tumor-initiating activity in breast, gastric, hepatocellular, and other cancers (PMID:21532620, PMID:24474766, PMID:25241036, PMID:39542206). FZD7 also transduces multiple non-canonical outputs: WNT11 binding engages a FZD7–DAAM1–Rho–ROCK–Myosin II axis controlling amoeboid invasion and metastasis (PMID:33082334); Wnt5a/b binding modulates PKC/ERK and STAT3/YAP1 signaling (PMID:28600110, PMID:32894152); and WNT7A drives a JAK1/STAT3 program independent of β-catenin, while in differentiated myofibres Wnt7a couples FZD7 to a Gαs/PI3K complex that activates Akt/mTOR anabolic growth (PMID:38246919, PMID:22179044). Receptor output is shaped by direct physical partners including GIPC2 (via PDZ interaction), Vangl1 at the leading edge of migrating cells, and LRP6 (PMID:35347223, PMID:37336284, PMID:32015160). FZD7 abundance is tightly controlled at multiple levels: transcriptionally by ΔNp63, PU.1 (downstream of SIRT7), NOTCH3, and the repressor BCL6 (PMID:25241036, PMID:39542206, PMID:26847503, PMID:37060074); post-transcriptionally by m6A/YTHDF1-mediated mRNA stabilization and translation (PMID:32788173, PMID:40281310); and post-translationally by ZNRF3-mediated ubiquitination and lysosomal degradation, which is promoted by RSPO2 and antagonized by Wnt5a (PMID:28600110, PMID:32015160). CryoEM has resolved full-length FZD7 in complex with the C. difficile toxin TcdB and structure-based screening has yielded transmembrane-domain antagonists (PMID:38308843, PMID:37669317).

Mechanistic history

Synthesis pass · year-by-year structured walk · 26 steps
  1. 2008 Medium

    Established FZD7 as a functional requirement for stem cell self-renewal, moving it from a catalogued Wnt receptor to a determinant of the pluripotent state.

    Evidence qRT-PCR enrichment and shRNA knockdown in human embryonic stem cells with OCT4 and germ-layer marker readouts

    PMID:18681827

    Open questions at the time
    • Did not define which Wnt ligand or downstream branch mediates the requirement
    • No co-receptor or effector identified
  2. 2011 Medium

    Showed FZD7 drives canonical Wnt/β-catenin output to sustain malignant proliferation and invasion, linking the receptor to tumor biology.

    Evidence shRNA knockdown in triple-negative breast cancer lines with nuclear β-catenin, TCF7 reporter, and xenograft readouts

    PMID:21532620

    Open questions at the time
    • Co-receptor requirement not addressed
    • Did not distinguish direct receptor signaling from secondary effects
  3. 2011 High

    Revealed a β-catenin-independent FZD7 mode in muscle, demonstrating direct coupling to a Gαs/PI3K complex for Akt/mTOR anabolic growth.

    Evidence Wnt7a treatment, reciprocal co-IP of Fzd7 with Gαs and PI3K, Akt/mTOR readouts, IGF-receptor independence in myofibres

    PMID:22179044

    Open questions at the time
    • Structural basis of Gαs/PI3K coupling unresolved
    • Generality beyond differentiated myofibres untested
  4. 2014 Medium

    Placed FZD7 downstream of ΔNp63 and as a node in pluripotency maintenance, connecting transcriptional control of the receptor to stem and tumor-initiating cell activity.

    Evidence ΔNp63 and FZD7 gain/loss-of-function with mammary/tumor-initiating assays; shRNA and FZD7-specific Fab in hESCs with Wnt3a signaling readouts

    PMID:24474766 PMID:25241036

    Open questions at the time
    • Mechanism of Fab-induced FZD7 down-regulation not detailed
    • Ligand identity in each stem context not pinned down
  5. 2014 Medium

    Implicated FZD7 in non-canonical Wnt/PCP control of cytoskeleton and Rho/Rac GTPase balance, broadening its output beyond β-catenin.

    Evidence siRNA knockdown in Stem-A ovarian cancer cells with RhoA/Rac1 activity assays, TopFlash, PCP gene profiling

    PMID:25032869

    Open questions at the time
    • Casein kinase 1ε role inferred from profiling rather than direct assay
    • Ligand driving the PCP branch not identified
  6. 2016 High

    Demonstrated an in vivo developmental requirement for FZD7 in angiogenesis acting via Dvl/β-catenin upstream of Notch ligand expression.

    Evidence Endothelial conditional Fzd7 knockout, Dvl depletion, LiCl rescue, and Dll4/Jagged1 readouts in retinal vasculature

    PMID:27758766

    Open questions at the time
    • Direct molecular link between FZD7 signaling and Notch target promoters not resolved
    • Wnt ligand identity in endothelium unspecified
  7. 2016 Medium

    Identified NOTCH3-specific, CSL-independent transcriptional control of FZD7, revealing cross-pathway regulation of receptor abundance.

    Evidence Gain/loss-of-function of NOTCH1-4 in breast epithelial cells with FZD7 expression and non-canonical signaling readouts

    PMID:26847503

    Open questions at the time
    • Direct DNA-binding mechanism of the NOTCH3 effect not shown
    • Physiological context of the regulation untested
  8. 2017 High

    Defined post-translational control of FZD7 surface levels through RSPO2/ZNRF3-mediated ubiquitination, with Wnt5a stabilizing the receptor to promote migration.

    Evidence Co-IP, ubiquitination assays, PKC/ERK readouts, and ligand competition in colorectal cancer cells

    PMID:28600110

    Open questions at the time
    • Whether other Wnt ligands modulate ZNRF3 access not tested
    • Quantitative balance of degradation versus stabilization in vivo unknown
  9. 2018 Medium

    Identified FZD7 as the cognate receptor for WNT10B in trophoblast migration, linking a specific ligand to Rac1-driven cytoskeletal remodeling.

    Evidence Receptor identification, migration and Rac1 assays, SFRP3 competition, trophoblast-decidual co-culture

    PMID:29979633

    Open questions at the time
    • Direct WNT10B-FZD7 binding affinity not quantified
    • Co-receptor involvement not addressed
  10. 2019 Medium

    Established tissue-specific FZD7 dependence among Wnt-driven stem cells, showing requirement in intestinal but not gastric Lgr5+ cells.

    Evidence Conditional Fzd7 deletion in gastric Lgr5+ cells with intestinal comparison and homeostasis/regeneration assays

    PMID:31288403

    Open questions at the time
    • Compensating FZD receptors in gastric tissue not identified
    • Molecular basis of differential requirement unresolved
  11. 2019 Medium

    Connected FZD7 to epigenetic activation of TWIST1 and downstream BCL2-mediated anoikis resistance, providing a transcriptional/epigenetic effector arm.

    Evidence FZD7 knockdown/overexpression, TWIST1 rescue, ChIP for H3K4me3/H3K27ac, anoikis and spheroid assays in ovarian cancer

    PMID:30548372

    Open questions at the time
    • How FZD7 signaling reaches chromatin modifiers at the TWIST1 promoter not defined
    • Branch (canonical vs non-canonical) responsible unclear
  12. 2020 High

    Resolved a WNT11-FZD7-DAAM1-Rho-ROCK-Myosin II axis driving amoeboid invasion and metastasis, formalizing a non-canonical effector cascade.

    Evidence KD/KO epistasis across WNT11, FZD7, DAAM1 in melanoma with Rho-ROCK-Myosin II readouts, in vivo metastasis, and human tissue validation

    PMID:33082334

    Open questions at the time
    • Direct FZD7-DAAM1 physical contact not structurally mapped
    • Receptor conformational changes coupling ligand to Rho activation unknown
  13. 2020 Medium

    Identified m6A/YTHDF1-mediated translational control of FZD7 mRNA as a layer of expression regulation feeding Wnt/β-catenin output.

    Evidence m6A-seq, YTHDF1 manipulation, translation/polysome assays in gastric cancer models

    PMID:32788173

    Open questions at the time
    • Specific m6A sites on FZD7 mRNA not pinpointed
    • Interplay with transcriptional regulators not examined
  14. 2020 Medium

    Showed Fzd7-Wnt5a/b non-canonical signaling shapes STAT3/Smad3/YAP1 activity and Col6a1-dependent mesenchymal stemness/EMT in breast cancer.

    Evidence Co-IP of Fzd7 with Wnt5a/b, pathway western blots, Col6a1 epistasis, xenograft/metastasis assays

    PMID:32894152

    Open questions at the time
    • Direct versus indirect engagement of each downstream effector not separated
    • Co-receptor requirement unaddressed
  15. 2020 High

    Reconstituted FZD7-selective receptor engagement, proving that bridging FZD7 to LRP6 is sufficient to activate β-catenin and program mesendodermal differentiation.

    Evidence Engineered F7L6 bispecific agonist, receptor-selectivity profiling, β-catenin reporters, and hPS cell transcriptomics

    PMID:33331818

    Open questions at the time
    • Endogenous Wnt ligand specificity for FZD7/LRP6 not resolved
    • Structural geometry of the productive FZD7-LRP6 complex not defined here
  16. 2020 Medium

    Demonstrated pharmacological degradation of the LRP6/FZD7 complex, showing FZD7 turnover can be coupled to its co-receptor's ectodomain.

    Evidence CDDO-Me degradation and ubiquitination assays, lysosomal inhibitors, LRP6 ectodomain deletion, and DVL2/β-catenin readouts in breast cancer

    PMID:32015160

    Open questions at the time
    • E3 ligase mediating CDDO-Me-induced degradation not identified
    • Specificity for FZD7 over other FZDs not assessed
  17. 2022 Medium

    Identified GIPC2 as a direct PDZ-domain partner of FZD7 that potentiates β-catenin signaling and prostate cancer metastasis, defining a cytoplasmic adaptor link.

    Evidence Co-IP, PDZ interaction mapping, β-catenin assays, and in vivo metastasis assays

    PMID:35347223

    Open questions at the time
    • How GIPC2 binding mechanistically enhances β-catenin output unclear
    • Reciprocal validation in other cell types absent
  18. 2022 Medium

    Linked FZD7 to Wnt5a-driven ABCG2 expression and chemoresistance, and to TGF-β/SMAD3 crosstalk in EMT, expanding its role in drug-resistant phenotypes.

    Evidence siRNA/inhibitor of FZD7 with ABCG2 and gemcitabine assays; FZD7 knockdown/overexpression with TGF-β1 stimulation and CSC readouts in pancreatic cancer

    PMID:33200805 PMID:35854234

    Open questions at the time
    • Direct receptor-level integration of Wnt and TGF-β inputs not demonstrated
    • Single-lab pathway placement
  19. 2023 Medium

    Resolved transcriptional repression of FZD7 by BCL6 and its connection to ferroptosis, adding a tumor-suppressive regulatory arm.

    Evidence ChIP, dual-luciferase reporter, rescue experiments, and ferroptosis readouts in gastric cancer

    PMID:37060074

    Open questions at the time
    • Mechanism connecting FZD7/β-catenin to GPX4-dependent ferroptosis not fully dissected
    • Physiological contexts of BCL6 repression unclear
  20. 2023 Medium

    Identified a Vangl1/Fzd7 leading-edge complex coupling the receptor to Rho GTPase-driven cytoskeletal dynamics in glioblastoma invasion.

    Evidence Co-IP, leading-edge co-localization, Rho GTPase assays, and intracranial xenograft with FZD7 depletion

    PMID:37336284

    Open questions at the time
    • Direct versus scaffolded interaction not distinguished
    • Ligand input to the Vangl1/Fzd7 complex unidentified
  21. 2023 Medium

    Delivered structure-based FZD7 transmembrane-domain antagonists, establishing the TMD as a druggable pocket.

    Evidence Structure-based virtual screening, compound F7H synthesis, Wnt/β-catenin antagonism reporter, and docking/MD/FEP

    PMID:37669317

    Open questions at the time
    • Binding-pocket residues defined computationally, not by experimental structure
    • Selectivity against other FZD TMDs not fully validated
  22. 2024 High

    Provided the first full-length FZD7 structure in complex with C. difficile TcdB, revealing conformational requirements for toxin engagement and antibody-based disruption.

    Evidence CryoEM of TcdB apo and TcdB-FZD7 complex, live-cell affinity, and bezlotoxumab competition

    PMID:38308843

    Open questions at the time
    • Structure of Wnt/Rspo-bound FZD7 not resolved
    • Signaling conformations distinct from toxin binding undefined
  23. 2024 Medium

    Established a WNT7A-FZD7-JAK1-STAT3 cascade that operates without β-catenin, cementing a distinct non-canonical signaling output.

    Evidence WNT7A overexpression, JAK1/STAT3 readouts, negative β-catenin reporter, and PDX model in head and neck carcinoma

    PMID:38246919

    Open questions at the time
    • How FZD7 physically couples to JAK1 not shown
    • Co-receptor requirement for the STAT3 branch unknown
  24. 2024 Medium

    Connected SIRT7 to FZD7 via PU.1-driven transcription, situating FZD7 as the obligatory node for SIRT7-mediated β-catenin stabilization in hepatocellular carcinoma.

    Evidence SIRT7/PU.1 manipulation, FZD7 knockdown rescue, fractionation, β-catenin stability/ubiquitination, and TopFlash assays

    PMID:39542206

    Open questions at the time
    • Direct PU.1 occupancy at the FZD7 promoter not detailed
    • Whether SIRT7 acts solely through PU.1 unresolved
  25. 2025 Medium

    Showed FZD7 imparts distinct β-catenin signaling kinetics that diversify mesoderm fate, and that YTHDF1-stabilized FZD7 sustains chemoresistance, reinforcing both developmental and oncogenic regulatory roles.

    Evidence FZD2/FZD7-selective agonists with β-catenin kinetics and mesoderm marker analysis in hPSCs; YTHDF1/m6A-IP, mRNA stability, and cisplatin-resistance xenografts in ovarian cancer

    PMID:39824186 PMID:40281310

    Open questions at the time
    • Receptor-intrinsic basis for faster β-catenin dampening by FZD7 not mechanistically defined
    • m6A site mapping on FZD7 mRNA incomplete
  26. 2025 Medium

    Identified BRAF-phosphorylated cytoplasmic KIAA1429 as a direct stabilizer of FZD7 protein driving Wnt activation and oxaliplatin resistance.

    Evidence Co-IP, immunofluorescence, RNA-seq, and oxaliplatin-resistance assays in colorectal cancer

    PMID:40611274

    Open questions at the time
    • Mechanism by which KIAA1429 binding blocks FZD7 turnover not defined
    • Relationship to ZNRF3-mediated degradation untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single FZD7 receptor selects among canonical β-catenin, PCP/Rho, STAT3, and Gαs/PI3K outputs in a given cell remains undefined at the structural and biochemical level.
  • No structure of a signaling-competent Wnt-FZD7-co-receptor complex
  • Determinants of canonical versus non-canonical branch choice unmapped
  • Quantitative contribution of each regulatory layer in vivo unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0048018 receptor ligand activity 2 GO:0001618 virus receptor activity 1
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4 R-HSA-1266738 Developmental Biology 3
Partners
DAAM1GIPC2KIAA1429LRP6RSPO2VANGL1WNT11ZNRF3
Complex memberships
FZD7-Gαs-PI3K complexFZD7-LRP6 receptor complexVangl1-FZD7 complex

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 FZD7 knockdown in triple-negative breast cancer cells (MDA-MB-231, BT-20) suppresses cell proliferation, invasiveness, and colony formation through silencing of canonical Wnt signaling, as evidenced by loss of nuclear β-catenin accumulation and decreased TCF7 transcriptional activity; in vivo xenograft studies confirmed reduced tumor formation. shRNA knockdown, β-catenin nuclear localization assay, TCF7 reporter assay, xenograft mouse model Oncogene Medium 21532620
2011 In differentiated myofibres, Wnt7a binding to Fzd7 directly activates the Akt/mTOR anabolic growth pathway via a receptor complex associated with Gαs and PI(3)K, independently of IGF-receptor activation, thereby inducing myofibre hypertrophy. Wnt7a ligand treatment, co-immunoprecipitation of Fzd7 with Gαs and PI3K, Akt/mTOR pathway readouts, IGF-receptor independence experiments Nature cell biology High 22179044
2014 ΔNp63 transcription factor promotes mammary stem cell activity and basal breast cancer tumor-initiating activity by increasing FZD7 expression, thereby enhancing Wnt signaling; FZD7-dependent Wnt signaling governed tumor-initiating activity of basal breast cancer. Gain- and loss-of-function of ΔNp63 and FZD7, mammary stem cell and tumor-initiating cell assays Nature cell biology Medium 25241036
2014 FZD7 is required for maintenance of the pluripotent state of human embryonic stem cells (hESCs); shRNA-mediated knockdown or blockade with a FZD7-specific Fab fragment disrupts pluripotency. The FZD7-specific Fab blocks Wnt3a signaling by down-regulating FZD7 protein levels, indicating that FZD7 transduces Wnt/β-catenin signals in hESCs. shRNA knockdown, FZD7-specific Fab antibody treatment, Wnt3a signaling assay, FZD7 protein level measurement Proceedings of the National Academy of Sciences of the United States of America Medium 24474766
2014 FZD7 knockdown in Stem-A ovarian cancer cells reduces proliferation, induces epithelial-like morphology, increases cadherin-based cell-cell adhesion, rearranges actin cytoskeleton, decreases RhoA activity, and increases Rac1 activity; increased TopFlash activity and PCP pathway gene regulation suggest FZD7 drives aggressiveness via the non-canonical Wnt/PCP pathway through casein kinase 1ε. siRNA knockdown, cell proliferation and morphology assays, immunofluorescence, RhoA/Rac1 activity assays, TopFlash reporter assay, PCP gene expression profiling Cell death & disease Medium 25032869
2008 FZD7 is expressed at up to 200-fold higher levels in human embryonic stem cells versus differentiated cell types; shRNA-mediated knockdown in hESCs induces changes in colony morphology, perturbation of germ layer marker gene expression, and rapid loss of OCT4 expression, establishing FZD7 as required for ES cell self-renewal capacity. Quantitative RT-PCR, flow cytometry, shRNA knockdown, OCT4 expression analysis Biological chemistry Medium 18681827
2016 Fzd7 expressed by endothelial cells is required for postnatal retinal vascular formation; endothelial cell-specific deletion of Fzd7 delays retinal plexus formation by impairing tip cell phenotype and stalk cell proliferation. Fzd7 acts via Dvl/β-catenin activation upstream of Notch signaling to control Dll4 and Jagged1 expression; LiCl treatment rescued the vascular phenotype of Fzd7 mutants. Conditional endothelial knockout mouse, retinal vascular phenotype analysis, Dvl3 depletion in dvl1-/- mice, LiCl pharmacological rescue, Notch target gene expression Arteriosclerosis, thrombosis, and vascular biology High 27758766
2017 RSPO2 physically interacts with Fzd7 and increases degradation of cell-surface Fzd7 via ZNRF3-mediated ubiquitination, suppressing downstream PKC/ERK signaling and CRC cell migration; Wnt5a prevents Fzd7 degradation and promotes CRC cell migration, while RSPO2 antagonizes Wnt5a/Fzd7 signaling by blocking Wnt5a binding to FZD7. Co-immunoprecipitation, ubiquitination assay, PKC/ERK signaling readouts, migration/invasion assays, ligand competition experiments Cancer letters High 28600110
2020 YTHDF1 promotes translation of FZD7 mRNA in an m6A-dependent manner in gastric cancer; mutated YTHDF1 enhances FZD7 expression, leading to hyperactivation of Wnt/β-catenin pathway. m6A-seq, YTHDF1 knockdown/overexpression, polysome profiling or translation assay, in vitro and in vivo gastric cancer models Cancer research Medium 32788173
2020 WNT11-FZD7-DAAM1 signaling activates the Rho-ROCK1/2-Myosin II pathway to regulate tumour-initiating potential, amoeboid invasion, local invasion, and distant metastasis in melanoma. KD/KO of WNT11, FZD7, DAAM1 in melanoma cells; Rho-ROCK-Myosin II signaling readouts; in vivo metastasis assays; human melanoma tissue analysis Nature communications High 33082334
2019 FZD7 regulates TWIST1 expression through epigenetic modifications (H3K4me3 and H3K27ac) at the TWIST1 proximal promoter; the FZD7-TWIST1 axis then regulates BCL2 expression to confer anoikis resistance in ovarian cancer. Overexpression of TWIST1 partially rescued phenotypes abolished by FZD7 knockdown. FZD7 knockdown/overexpression, TWIST1 overexpression rescue, chromatin immunoprecipitation for H3K4me3/H3K27ac, BCL2 expression analysis, anoikis and spheroid assays Molecular oncology Medium 30548372
2020 Non-canonical Fzd7 signaling in breast cancer cells involves Fzd7 binding to Wnt5a/b, and modulates phospho-STAT3, Smad3, YAP1, and Col6a1 expression; Fzd7-Wnt5b regulates Col6a1 to mediate mesenchymal-like stemness and EMT. Fzd7 knockdown/overexpression, co-immunoprecipitation of Fzd7 with Wnt5a/b, pathway protein western blots, Col6a1 knockdown epistasis, xenograft and metastasis assays Cell communication and signaling : CCS Medium 32894152
2022 GIPC2 directly binds to FZD7 through its PDZ domain, enabling activation of WNT-β-catenin cascades and stimulating prostate cancer metastasis. Co-immunoprecipitation, PDZ domain interaction mapping, β-catenin signaling assays, in vitro and in vivo metastasis assays Oncogene Medium 35347223
2020 Selective engagement of FZD7 (and not other FZD proteins) by the engineered bispecific protein F7L6, which bridges FZD7 and LRP6, potently activates WNT/β-catenin signaling and is sufficient to initiate mesendodermal differentiation programs in human pluripotent stem cells, mimicking primitive streak formation. Engineered FZD7-selective/LRP6-bridging agonist (F7L6), WNT/β-catenin reporter assays, transcriptome profiling of hPS cells, comparison with Wnt3a and other FZD-selective agonists eLife High 33331818
2024 CryoEM structures of TcdB alone and in complex with full-length FZD7 reveal that large structural rearrangements of the combined repetitive polypeptide (CROPs) domain of TcdB are required for FZD7 interaction; bezlotoxumab (FDA-approved antibody) favors the apo-TcdB conformation and disrupts FZD7 binding. Dynamic transition between TcdB conformations also governs stability of the pore-forming region. CryoEM structure determination, live-cell affinity assay, bezlotoxumab competition binding assay Cell reports High 38308843
2023 Structure-based ligand discovery targeting the transmembrane domain (TMD) of FZD7 identified compound F7H as an FZD7 antagonist (IC50 = 1.25 μM); molecular docking, MD simulation, and free energy perturbation calculations defined key binding-pocket residues in the TMD. Structure-based virtual screening, compound synthesis, Wnt/β-catenin reporter antagonism assay, molecular docking/MD/FEP calculations Journal of medicinal chemistry Medium 37669317
2020 CDDO-Me inhibits Wnt/β-catenin signaling by inducing ubiquitination and lysosomal degradation of the LRP6/FZD7 receptor complex; degradation of FZD7 is dependent on the LRP6 ectodomain, and CDDO-Me reduces phospho-DVL2 and active β-catenin levels in breast cancer cells. LRP6 and FZD7 protein degradation assays, ubiquitination assay, lysosomal pathway inhibitors, LRP6 ectodomain deletion constructs, DVL2 and β-catenin western blots, xenograft model The Journal of pharmacology and experimental therapeutics Medium 32015160
2016 NOTCH3, but not NOTCH1, 2, or 4, regulates FZD7 expression in human breast epithelial cells through a non-canonical (CSL-independent) Notch signaling mechanism; gain- and loss-of-function experiments showed this regulation is unique and non-redundant. Constitutively active NOTCH1-4 overexpression, NOTCH loss-of-function, CSL-independent signaling assay, FZD7 expression analysis Stem cells and development Medium 26847503
2018 GCM1 transcription factor promotes trophoblast cell migration by activating WNT10B expression; WNT10B signals through FZD7 (identified as its cognate receptor) to upregulate cell migration via Rac1-mediated cytoskeletal remodeling. SFRP3 from decidual cells blocks WNT10B-FZD7 interaction to decrease trophoblast migration. FZD7 receptor identification for WNT10B, cell migration assays, Rac1 activity assays, SFRP3 competition binding, trophoblast-decidual co-culture FASEB journal Medium 29979633
2023 Vangl1 forms a novel complex with Fzd7 at the leading edge of migrating GBM cells; this Vangl1/Fzd7 complex drives cellular proliferation, migration, and invasiveness by engaging Rho GTPases to promote cytoskeletal rearrangements and actin dynamics. Co-immunoprecipitation, co-localization at leading edge, Rho GTPase activity assays, FZD7 depletion in intracranial xenograft model, KD functional assays Cancer letters Medium 37336284
2024 SIRT7 promotes FZD7 expression by upregulating the transcription factor PU.1, which then drives FZD7 transcription; FZD7 is required for SIRT7-mediated stabilization of β-catenin and its nuclear localization in hepatocellular carcinoma cells. FZD7 knockdown reversed SIRT7-overexpression-mediated β-catenin stabilization. SIRT7 knockdown/overexpression, FZD7 knockdown rescue, PU.1 manipulation, nuclear/cytoplasmic fractionation, β-catenin ubiquitination and stability assays, Top-Flash reporter, immunofluorescence Life sciences Medium 39542206
2023 BCL6 transcription repressor directly binds the FZD7 promoter and transcriptionally represses FZD7 to inhibit gastric cancer cell proliferation and metastasis; BCL6 also promotes ferroptosis through the FZD7/β-catenin/TP63/GPX4 pathway. ChIP assay, dual luciferase reporter assay, FZD7 rescue experiments, ferroptosis readouts (lipid peroxidation, MDA, Fe2+), rescue experiments Cell & bioscience Medium 37060074
2022 Wnt5a regulates ABCG2 expression in pancreatic cancer cells through FZD7; siRNA silencing or pharmacological inhibition of FZD7 blocked Wnt5a-induced ABCG2 upregulation and attenuated gemcitabine resistance. siRNA knockdown of FZD7, FZD7 inhibitors, recombinant Wnt5a treatment, ABCG2 expression analysis, gemcitabine resistance assay Molecular medicine reports Medium 33200805
2025 FZD7 activation (via selective agonist) triggers β-catenin signaling with distinct kinetics from FZD2, enabling both paraxial and lateral mesoderm differentiation of hPSCs, whereas FZD2 activation favors only paraxial mesoderm; FZD7 shows more rapid dampening of β-catenin signaling than FZD2, permitting lateral mesoderm induction. FZD2- and FZD7-selective antibody-based agonists, hPSC directed differentiation assays, β-catenin signaling kinetics measurement, mesoderm subtype marker analysis Stem cell reports Medium 39824186
2025 YTHDF1 binds to m6A-modified FZD7 mRNA in cisplatin-resistant ovarian cancer cells, enhancing its stability and translation, thereby sustaining Wnt/β-catenin signaling activation; YTHDF1 silencing reduces FZD7 expression, inhibits Wnt/β-catenin signaling, and restores cisplatin sensitivity in vitro and in xenograft models. YTHDF1 knockdown/overexpression, m6A-IP, mRNA stability assay, FZD7 expression analysis, Wnt/β-catenin pathway readouts, xenograft mouse model Apoptosis Medium 40281310
2022 FZD7 knockdown in pancreatic cancer cells reduces EMT marker expression, reduces mesenchymal phenotype, decreases cancer stem cell proportions (CD24+CD44+, ABCG2), and attenuates TGF-β1-induced EMT; FZD7 acts through both canonical Wnt/β-catenin and TGF-β/SMAD3 signaling pathways. lentiviral shRNA knockdown, FZD7 overexpression, TGF-β1 stimulation assays, EMT marker western blots, CSC flow cytometry, sphere formation assays Molecular medicine (Cambridge, Mass.) Medium 35854234
2024 WNT7A activates the FZD7/JAK1/STAT3 signaling pathway in head and neck squamous cell carcinoma, leading to enhanced cell proliferation, self-renewal, and resistance to apoptosis, without activating canonical Wnt/β-catenin signaling. WNT7A overexpression, FZD7/JAK1/STAT3 pathway analysis, β-catenin reporter (negative result), patient-derived xenograft model International journal of oral science Medium 38246919
2025 Cytoplasmic KIAA1429, phosphorylated by BRAF, stabilizes FZD7 protein in colorectal cancer cells by direct binding, thereby activating the WNT pathway and promoting cancer stemness and oxaliplatin resistance. Co-immunoprecipitation, immunofluorescence, RNA-seq, in vitro and in vivo oxaliplatin resistance assays, FZD7 stabilization experiments Journal of experimental & clinical cancer research Medium 40611274
2019 Fibronectin promotes non-canonical Wnt signaling through Wnt11-Fzd7 interaction in limbal epithelial stem cells, and modulates cell cycle regulators via upregulation of ROCK1 and ROCK2 to enhance stem cell self-renewal and proliferation. Wnt11 and Fzd7 co-expression/interaction analysis, ROCK inhibition, proliferation and stemness assays under fibronectin conditions Experimental eye research Low 31150636
2019 FZD7 knockdown reduces expression of Lgr5 (a WNT target) and is required for intestinal stem cell function in mice, but gastric Lgr5+ stem cells do not require Fzd7 for epithelial homeostasis, establishing tissue-specific differential requirement for FZD7 in Wnt-dependent stem cell maintenance. Conditional Fzd7 deletion in gastric Lgr5+ cells, intestinal comparison, homeostasis and regeneration assays Biomedicines Medium 31288403

Source papers

Stage 0 corpus · 84 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 231 21532620
2020 YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer research 201 32788173
2011 Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nature cell biology 194 22179044
2014 ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nature cell biology 190 25241036
2021 Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. Journal of hepatology 185 34509526
2001 Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. International journal of oncology 136 11408930
2014 FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell death & disease 109 25032869
2014 The WNT receptor FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 96 24474766
2018 Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells. Phytomedicine : international journal of phytotherapy and phytopharmacology 87 29747752
2015 MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 79 25976503
2020 WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nature communications 73 33082334
2011 Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 68 21472018
2017 RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway. Cancer letters 60 28600110
2019 miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway. Journal of experimental & clinical cancer research : CR 59 31419987
2014 MiR-199a regulates cell proliferation and survival by targeting FZD7. PloS one 56 25313882
2001 Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life sciences 50 11798016
2008 The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biological chemistry 48 18681827
2021 LncRNA HOTAIR promotes breast cancer progression through regulating the miR-129-5p/FZD7 axis. Cancer biomarkers : section A of Disease markers 47 33104019
2018 hsa_circ_0000177-miR-638-FZD7-Wnt Signaling Cascade Contributes to the Malignant Behaviors in Glioma. DNA and cell biology 42 30010402
2016 MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. Biochemical and biophysical research communications 40 27815069
2022 FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling. Molecular medicine (Cambridge, Mass.) 35 35854234
2019 MicroRNA-488 inhibits endometrial glandular epithelial cell proliferation, migration, and invasion in endometriosis mice via Wnt by inhibiting FZD7. Journal of cellular and molecular medicine 35 30729701
2016 Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget 35 27852064
2018 LncRNA AWPPH promotes the growth of triple-negative breast cancer by up-regulating frizzled homolog 7 (FZD7). Bioscience reports 33 30333256
2021 Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer. Drug discovery today 32 34915171
2017 Antitumor effect of miR-27b-3p on lung cancer cells via targeting Fzd7. European review for medical and pharmacological sciences 31 29028088
2021 Circular RNA circCSPP1 knockdown attenuates doxorubicin resistance and suppresses tumor progression of colorectal cancer via miR-944/FZD7 axis. Cancer cell international 30 33663510
2020 Non-canonical Fzd7 signaling contributes to breast cancer mesenchymal-like stemness involving Col6a1. Cell communication and signaling : CCS 28 32894152
2019 The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. Molecular oncology 28 30548372
2019 LncRNA AWPPH promotes osteosarcoma progression via activation of Wnt/β-catenin pathway through modulating miR-93-3p/FZD7 axis. Biochemical and biophysical research communications 28 31092328
2017 MicroRNA-27b inhibits cell proliferation in oral squamous cell carcinoma by targeting FZD7 and Wnt signaling pathway. Archives of oral biology 28 28735227
2016 Fzd7 (Frizzled-7) Expressed by Endothelial Cells Controls Blood Vessel Formation Through Wnt/β-Catenin Canonical Signaling. Arteriosclerosis, thrombosis, and vascular biology 28 27758766
2007 Comparative integromics on FZD7 orthologs: conserved binding sites for PU.1, SP1, CCAAT-box and TCF/LEF/SOX transcription factors within 5'-promoter region of mammalian FZD7 orthologs. International journal of molecular medicine 28 17273804
2021 A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Molecular cancer therapeutics 27 34667113
2010 Variable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment. Developmental dynamics : an official publication of the American Association of Anatomists 27 19655379
2022 GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling. Oncogene 26 35347223
2021 Fzd7/Wnt7b signaling contributes to stemness and chemoresistance in pancreatic cancer. Cancer medicine 26 33934523
2022 CircRNA_Maml2 promotes the proliferation and migration of intestinal epithelial cells after severe burns by regulating the miR-93-3p/FZD7/Wnt/β-catenin pathway. Burns & trauma 23 35265724
2020 Selective activation of FZD7 promotes mesendodermal differentiation of human pluripotent stem cells. eLife 22 33331818
2019 Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway. Oncology letters 21 31289540
2016 Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor. Bioengineered 21 27849134
2022 An investigation of bacteriocin nisin anti-cancer effects and FZD7 protein interactions in liver cancer cells. Chemico-biological interactions 20 36084725
2019 Fibronectin regulates the self-renewal of rabbit limbal epithelial stem cells by stimulating the Wnt11/Fzd7/ROCK non-canonical Wnt pathway. Experimental eye research 20 31150636
2020 CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex. The Journal of pharmacology and experimental therapeutics 19 32015160
2018 Aberrant Expression of miR-142-3p and its Target Gene HMGA1 and FZD7 in Breast Cancer and its Clinical Significance. Clinical laboratory 19 29945308
2016 FZD7 regulates BMSCs-mediated protection of CML cells. Oncotarget 18 26716419
2023 The malignancy suppression and ferroptosis facilitation of BCL6 in gastric cancer mediated by FZD7 repression are strengthened by RNF180/RhoC pathway. Cell & bioscience 17 37060074
2020 Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells. Molecular medicine reports 17 33200805
2018 Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes. Breast cancer research and treatment 17 29411237
2022 Exosomal FZD-7 Expression Is Modulated by Different Lifestyle Interventions in Patients with NAFLD. Nutrients 15 35334792
2018 Structural and dynamic characterization of human Wnt2-Fzd7 complex using computational approaches. Journal of molecular modeling 14 30191337
2024 WNT7A promotes tumorigenesis of head and neck squamous cell carcinoma via activating FZD7/JAK1/STAT3 signaling. International journal of oral science 13 38246919
2020 CircSAMD4A regulates cell progression and epithelial‑mesenchymal transition by sponging miR‑342‑3p via the regulation of FZD7 expression in osteosarcoma. International journal of molecular medicine 13 32319545
2016 Notch-Induced Expression of FZD7 Requires Noncanonical NOTCH3 Signaling in Human Breast Epithelial Cells. Stem cells and development 13 26847503
2005 Comparative genomics on Fzd7 orthologs. International journal of molecular medicine 12 15870913
2020 MicroRNA-1 Modulates Chondrocyte Phenotype by Regulating FZD7 of Wnt/ β-Catenin Signaling Pathway. Cartilage 11 33215510
2023 A complex of Wnt/planar cell polarity signaling components Vangl1 and Fzd7 drives glioblastoma multiforme malignant properties. Cancer letters 10 37336284
2018 SFRP3 negatively regulates placental extravillous trophoblast cell migration mediated by the GCM1-WNT10B-FZD7 axis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 10 29979633
2017 MicroRNA‑613 inhibits proliferation and invasion of renal cell carcinoma cells through targeting FZD7. Molecular medicine reports 10 29067457
2024 Structural and functional insight into the interaction of Clostridioides difficile toxin B and FZD7. Cell reports 9 38308843
2023 Structure-Based Ligand Discovery Targeting the Transmembrane Domain of Frizzled Receptor FZD7. Journal of medicinal chemistry 9 37669317
2022 MiR-1-3p enhances the sensitivity of ovarian cancer cells to ferroptosis by targeting FZD7. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 9 36481629
2024 FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer. ACS omega 8 38559981
2016 Short hairpin RNA silencing of TGF-βRII and FZD-7 synergistically suppresses proliferation and metastasis of hepatocellular carcinoma cells. Oncology letters 7 26998118
2024 SIRT7 stabilizes β-catenin and promotes canonical Wnt activation via upregulating FZD7. Life sciences 6 39542206
2019 Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response. Disease markers 6 31827644
2025 YTHDF1-mediated m6A modification promotes cisplatin resistance in ovarian cancer via the FZD7/Wnt/β-catenin pathway. Apoptosis : an international journal on programmed cell death 5 40281310
2023 FZD7, Regulated by Non-CpG Methylation, Plays an Important Role in Immature Porcine Sertoli Cell Proliferation. International journal of molecular sciences 5 37047150
2025 Silencing of FZD7 Inhibits Endometriotic Cell Viability, Migration, and Angiogenesis by Promoting Ferroptosis. Cell biochemistry and biophysics 4 39797998
2025 Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAFV600E-mutated colorectal cancer. Journal of experimental & clinical cancer research : CR 4 40611274
2024 HAS2 facilitates glioma cell malignancy and suppresses ferroptosis in an FZD7-dependent manner. Cancer science 4 38816349
2025 Selective activation of FZD2 and FZD7 reveals non-redundant function during mesoderm differentiation. Stem cell reports 2 39824186
2025 G-protein-coupled receptor FZD7 as a therapeutic target in glioblastoma: Multi-cohort validation and identification of Cycloartobiloxanthone as an inhibitor. Bioorganic chemistry 2 40412223
2023 FZD7: A potential biomarker for endometriosis. Medicine 2 37800830
2023 Mechanism of miR-548b-5p down-regulating FZD7 to impede the migratory and invasive behavior of gastric carcinoma cells. Cellular and molecular biology (Noisy-le-Grand, France) 2 38279460
2022 Anti-tumor activity of a recombinant soluble Fzd7 decoy receptor in human gastric and colon cancer cells. Iranian journal of basic medical sciences 2 35655594
2022 Antitumor effect and mechanism of FZD7 polypeptide vaccine. Frontiers in oncology 2 36276155
2021 A missense mutation in the FZD7 gene is associated with dilution of the red areas of the coat in Montbéliarde cattle. Animal genetics 2 33686687
2019 The Function of Lgr5+ Cells in the Gastric Antrum Does Not Require Fzd7 or Myc In Vivo. Biomedicines 2 31288403
2025 N6-methyladenosine regulated FZD7 inhibits ferroptosis in endometriosis via β-catenin/SLC7A11 pathway. Free radical biology & medicine 1 41241001
2025 LINC00888 Promotes Gastric Cancer Growth and Metastasis by Sponging miR-145-5p to Regulate FZD7 Expression. Combinatorial chemistry & high throughput screening 0 41177801
2025 FZD7 expression marks mammary tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America 0 41218118
2025 USP30-AS1 Dictates Breast Cancer Cell Fate and Chemoresistance via a miR-3646/FZD7/Wnt/β-Catenin Circuit. Current issues in molecular biology 0 41614739
2024 [Retracted] Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway. Oncology letters 0 38690102

Missed literature

Know a paper Affinage missed for FZD7? Flag it for the maintainers and the community.

No submissions yet.